GLP1R, GIPR, GCGR, and MC4R Incretin-Melanocortin Metabolic Signaling

GLP1R, GIPR, GCGR, and MC4R constitute the neuroendocrine receptor network that coordinates postprandial enteroinsular incretin insulin secretion, hepatic lipid oxidation, gastric emptying, and hypothalamic energy homeostasis in vertebrates. At the peripheral gut–pancreas–liver interface, three Class B1 (secretin-like) G-protein-coupled receptors (GPCRs)—the glucagon-like peptide-1 receptor (GLP1R on chromosome 6p21.2), the glucose-dependent insulinotropic polypeptide receptor (GIPR on Chr19q13.32), and the glucagon receptor (GCGR on subtelomeric Chr17q25.3)—respond to structurally homologous peptide hormones cleaved from proglucagon (GCG) and pro-GIP (GIP). In the central nervous system, vagal and area postrema/arcuate nucleus (ARC) signals from GLP1R and GIPR converge upon the leptin–pro-opiomelanocortin (POMC)–melanocortin-4 receptor (MC4R on Chr18q21.32) axis, a Class A rhodopsin-like GPCR circuit that sets the central threshold for satiety and sympathetic thermogenesis.

Over the past decade, large-scale human exome sequencing and cryo-electron microscopy (cryo-EM) of active-state receptor–G_s complexes have transformed metabolic drug discovery. Naturally occurring coding variants in GLP1R (p.Ala316Thr) and GIPR (p.Glu354Gln, p.Arg18Gln) protect against type 2 diabetes (T2D) and adiposity, whereas heterozygous loss-of-function mutations in MC4R account for 5% to 6% of early-onset monogenic obesity (~1 in 300 individuals). These structural and genetic insights guided the rational engineering of long-acting mono-agonists (semaglutide), biased dual GIP/GLP-1 co-agonists (tirzepatide), triple GIP/GLP-1/GCG tri-agonists (retatrutide), oral small-molecule GLP1R agonists (orforglipron), and targeted melanocortin-4 cyclic peptide agonists (setmelanotide).

Two-Domain Peptide Binding and Gαs–cAMP–PKA/EPAC2 Transduction

GLP1R (463 amino acids), GIPR (466 amino acids), and GCGR (477 amino acids) belong to the 15-member Class B1 secretin receptor subfamily, characterized by an extracellular N-terminal domain (ECD, ~120–150 residues) stabilized by three conserved disulfide bridges (Cys-Cys) and a seven-transmembrane (7TM) α-helical bundle lacking the canonical DRY motif of Class A GPCRs (replaced by a polar Het-Glu-Thr-Tyr (HETY) network at the cytoplasmic base of TM2–TM3–TM6–TM7). Peptide ligand recognition proceeds via a two-step "affinity-trap" mechanism:

1. C-Terminal Amphipathic α-Helix Capture by the ECD: The C-terminal half (residues 16–30) of endogenous GLP-1(7–36)NH₂ (secreted by ileal/colonic enteroendocrine L-cells), GIP(1–42) (from duodenal K-cells), or glucagon (GCG(1–29)) (from pancreatic α-cells) folds into an amphipathic α-helix that docks into a hydrophobic groove on the extracellular ECD (K_d ≈ 10–100 nM).
2. N-Terminal Orthosteric Insertion and TM6 Outward Kink: The N-terminal residues (His7–Ala8–Glu9 in GLP-1; Tyr1–Ala2–Glu3 in GIP; His1–Ser2–Gln3 in GCG) plunge deep into the 7TM core, disrupting the central polar network (Arg190^2.60, Asn240^3.43, His363^6.52, Gln394^7.49 in GLP1R) and inducing a sharp 60° outward kink of transmembrane helix 6 (TM6) around the conserved Pro358^6.47–X–X–Gly361^6.50 (PXXG) motif.

This TM6 outward displacement opens a cytoplasmic cavity that engages the C-terminal α5 helix of the heterotrimeric Gα_s subunit, stimulating transmembrane adenylyl cyclase (AC) to convert ATP into 3′,5′-cyclic adenosine monophosphate (cAMP). In pancreatic β-cells, elevated cAMP activates both protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2 / RAPGEF4). Together, PKA and EPAC2 phosphorylate sulfonylurea receptor 1 (SUR1) to close ATP-sensitive potassium (K_ATP) channels, sensitize Ryanodine (RyR2) and IP₃ receptors to amplify intracellular Ca²⁺ oscillations, and prime insulin-granule exocytosis—strictly when extracellular glucose exceeds ~4.5–5.0 mM (preventing hypoglycemia at fasting glucose levels).

Why Biased GLP1R Signaling and GIPR Co-Agonism Amplify Weight Loss

Native GLP-1(7–36)NH₂ has an in vivo plasma half-life of only 1.5 to 2 minutes due to rapid N-terminal cleavage after Ala8 by dipeptidyl peptidase-4 (DPP-4) and renal filtration. First- and second-generation GLP-1 analogues (semaglutide, t_1/2 ≈ 165 hours) incorporate an α-aminoisobutyric acid (Aib8) substitution to block DPP-4 proteolysis and a C18 fatty diacid chain at Lys26 that binds reversibly to serum albumin, achieving ~14.9% to 16.9% body weight loss via GLP1R-expressing glutamatergic and GABAergic neurons in the area postrema (AP), nucleus tractus solitarius (NTS), and arcuate nucleus (ARC).

However, full orthosteric activation of GLP1R by GLP-1 or semaglutide strongly recruits β-arrestin-1 and β-arrestin-2 via G-protein-coupled receptor kinases (GRK2/GRK5), driving clathrin-mediated GLP1R internalization and tachyphylaxis while triggering area postrema emetic reflexes (nausea and vomiting). In contrast, the dual agonist tirzepatide displays profound G_s-protein signaling bias at GLP1R: it stimulates cAMP generation while recruiting <10% of the β-arrestin induced by native GLP-1, leaving GLP1R receptors active on the plasma membrane (SURMOUNT trials: 20.9% to 22.5% weight loss). Simultaneously, tirzepatide acts as a full agonist at GIPR, which enhances white adipose tissue insulin sensitivity and lipoprotein lipase (LPL) lipid buffering while activating inhibitory GABAergic GIPR⁺ neurons in the area postrema that directly suppress GLP1R-induced nausea, allowing higher therapeutic dose escalation.

Adding Hepatic GCGR: Retatrutide and Survodutide in MASH

Crucially, mature human hepatocytes do not express GLP1R or GIPR; thus, semaglutide and tirzepatide reduce liver fat indirectly through systemic weight loss and improved adipose insulin sensitivity. By contrast, hepatocytes abundantly express the glucagon receptor (GCGR). Although isolated chronic hyperglucagonemia promotes hepatic glycogenolysis and gluconeogenesis (PEPCK, G6PC), pairing GCGR agonism with potent GLP1R/GIPR insulinotropism (as in the triple agonist retatrutide or dual GLP-1/GCG agonist survodutide) buffers hepatic glucose output while directly activating hepatocyte GCGR–cAMP–PKA–AMPK signaling. This phosphorylates and inhibits acetyl-CoA carboxylase (ACC1/ACC2), lowers malonyl-CoA, activates carnitine palmitoyltransferase 1A (CPT1A), and stimulates mitochondrial fatty acid β-oxidation and oxidative phosphorylation—clearing >80% of hepatic triglycerides within 24 to 48 weeks.

α-MSH vs AgRP Competition and Gαq/11–PLCβ Bias at MC4R

Within the hypothalamic arcuate nucleus (ARC), adipocyte-secreted leptin (LEP) binds the long isoform of the leptin receptor (LEPRb), activating JAK2–STAT3 to stimulate transcription of pro-opiomelanocortin (POMC) while inhibiting adjacent orexigenic neurons that co-express neuropeptide Y (NPY) and agouti-related peptide (AgRP). Prohormone convertase 1/3 (PCSK1) and carboxypeptidase E cleave POMC into α-melanocyte-stimulating hormone (α-MSH) and β-MSH, which are released onto second-order neurons in the paraventricular nucleus (PVN) expressing the melanocortin-4 receptor (MC4R).

Encoded by an intronless coding exon on chromosome 18q21.32 (332 amino acids), MC4R is a Class A GPCR whose orthosteric pocket coordinates a mandatory Ca²⁺ ion (via Glu100^2.60, Asp122^3.25, and Asp126^3.29) required for binding the conserved His6–Phe7–Arg8–Trp9 (HFRW) pharmacophore of α-MSH. Meanwhile, AgRP acts as both a competitive antagonist and an inverse agonist that suppresses high basal constitutive MC4R activity. Human genetic studies of over 500,000 UK Biobank participants (Lotta et al.) revealed that while MC4R canonically signals via Gα_s–cAMP, human MC4R variants (p.Val103Ile, p.Ile251Leu) that selectively enhance β-arrestin recruitment and Gα_q/11–phospholipase Cβ (PLCβ)–Ca²⁺/NFAT signaling strongly protect against human obesity and type 2 diabetes (OR ≈ 0.52), whereas variants impairing Gα_q/11 coupling cause hyperphagic obesity even when cAMP production is preserved. The cyclic octapeptide setmelanotide (Imcivree) binds MC4R with 20-fold higher potency than endogenous α-MSH and potently activates Gα_q/11–PLCβ, bypassing upstream defects in LEPR, POMC, or PCSK1 to restore satiety and induce 10% to 25% weight loss in patients with monogenic hypothalamic obesity.

How does tirzepatide achieve greater weight loss with less nausea per unit of GLP1R activation than selective GLP-1 agonists?

Tirzepatide combines two complementary mechanisms: first, at GLP1R, it acts as a G_s-biased agonist that stimulates cAMP synthesis while recruiting <10% of β-arrestin, preventing receptor internalization (desensitization) on β-cells and anorectic neurons. Second, its full agonism at GIPR activates inhibitory GABAergic GIPR⁺ neurons in the area postrema (hindbrain emetic center) that directly blunt GLP1R-driven nausea and vomiting, permitting higher clinical dosing.

Why do triple agonists (retatrutide) clear hepatic fat faster than GLP-1 or GIP/GLP-1 agonists?

Human hepatocytes lack GLP1R and GIPR receptors, so semaglutide and tirzepatide lower liver fat only indirectly via systemic weight loss. Retatrutide adds agonism at the glucagon receptor (GCGR), which is densely expressed on hepatocytes. Hepatic GCGR activation inhibits acetyl-CoA carboxylase (ACC), activates CPT1A, and directly drives mitochondrial fatty acid β-oxidation, eliminating >80% of hepatic steatosis while concurrent GLP-1/GIP activity prevents glucagon-induced hyperglycemia.

How does setmelanotide treat genetic obesity caused by POMC, PCSK1, or LEPR deficiency?

In patients with biallelic loss-of-function mutations in LEPR, POMC, or PCSK1, the hypothalamic arcuate nucleus fails to synthesize or release endogenous α-MSH, leaving downstream MC4R receptors in the paraventricular nucleus unstimulated and causing insatiable hyperphagia from infancy. Setmelanotide is a protease-resistant cyclic octapeptide that acts directly on intact downstream MC4R receptors (Gα_s and Gα_q/11–PLCβ pathways), restoring the missing melanocortin satiety signal.

1. Zhang, Y., Sun, B., Feng, D., et al. (2017). "Cryo-EM structure of the GLP-1 receptor in complex with a Gs protein." Nature, 546(7657), 248–253. https://doi.org/10.1038/nature22394
2. Willard, F. S., Douros, J. D., Gabe, M. B., et al. (2020). "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist." JCI Insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532
3. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
4. Lotta, L. A., Mokrosiński, J., Mendes de Oliveira, E., et al. (2019). "Human gain-of-function MC4R variants show signaling bias and protect against obesity." Cell, 177(3), 597–607. https://doi.org/10.1016/j.cell.2019.03.044